Breda, Netherlands

Argen-X N.v.


USPTO Granted Patents = 11


Forward Citations = 76

Loading Chart...
Loading Chart...

19 inventors (with patents filed for the assignee):

goldMedal Torsten Dreier (9 out of 27 patents)

silverMedal Natalie De Jonge (6 out of 10 patents)

bronzeMedal Johannes Joseph Wilhelmus De Haard (6 out of 34 patents)

4.  Anna Hultberg (5 out of 8 patents)

5.  Johannes De Haard (5 out of 12 patents)

6.  Michael Saunders (4 out of 13 patents)

7.  Els Festjens (4 out of 6 patents)

8.  Karen Silence (3 out of 24 patents)

9.  Peter Ulrichts (3 out of 10 patents)

10.  Christophe Blanchetot (2 out of 24 patents)

11.  Paolo Michieli (2 out of 12 patents)

12.  Michael John Scott Saunders (2 out of 24 patents)

13.  Harald Wajant (2 out of 6 patents)

14.  Sofie Maria Elvire Gabriels (2 out of 5 patents)

15.  Mahan Moshir (2 out of 7 patents)


11 patents:

Company Overview
Argen-X N.V. is a biotechnology company based in Breda, Netherlands, specializing in the development of innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary antibody engineering platform to create differentiated therapeutic candidates that target unmet medical needs. With a focus on advancing its pipeline through clinical development, Argen-X aims to improve patient outcomes by harnessing the power of the immune system.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

11 Patents

#9 in Breda

#569 in Netherlands

#51,761 in the World

Breda, NL
Breda, Netherlands
Forward Citations = 76

19 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Argen-X N.v.. Retrieved from https://idiyas.com/company/argen-x-n-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…